Constellation Pharmaceuticals Inc (NASDAQ:CNST) saw a large growth in short interest during the month of November. As of November 29th, there was short interest totalling 1,920,000 shares, a growth of 34.3% from the November 14th total of 1,430,000 shares. Currently, 16.2% of the shares of the company are sold short. Based on an average trading volume of 517,400 shares, the short-interest ratio is currently 3.7 days.
In other news, major shareholder Group L. P. Column bought 1,411,764 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The stock was purchased at an average price of $8.50 per share, with a total value of $11,999,994.00. Also, major shareholder Of The University Of C. Regents sold 187,116 shares of Constellation Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.48, for a total value of $7,200,223.68. Insiders sold a total of 317,971 shares of company stock valued at $10,976,079 in the last 90 days. 43.70% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in shares of Constellation Pharmaceuticals by 42.1% in the 2nd quarter. Wells Fargo & Company MN now owns 13,937 shares of the company’s stock valued at $171,000 after purchasing an additional 4,132 shares during the period. Alps Advisors Inc. acquired a new stake in Constellation Pharmaceuticals during the second quarter valued at $663,000. Acadian Asset Management LLC acquired a new stake in Constellation Pharmaceuticals during the second quarter valued at $61,000. Northern Trust Corp increased its holdings in Constellation Pharmaceuticals by 12.7% in the second quarter. Northern Trust Corp now owns 146,358 shares of the company’s stock valued at $1,797,000 after buying an additional 16,548 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Constellation Pharmaceuticals by 13.0% in the second quarter. BlackRock Inc. now owns 820,432 shares of the company’s stock valued at $10,074,000 after buying an additional 94,107 shares in the last quarter. 60.63% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have commented on CNST. ValuEngine cut shares of Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Royal Bank of Canada raised their target price on shares of Constellation Pharmaceuticals to $42.00 and gave the stock a “positive” rating in a report on Thursday, November 7th. Robert W. Baird restated an “outperform” rating and set a $65.00 target price (up from $35.00) on shares of Constellation Pharmaceuticals in a research report on Tuesday. Zacks Investment Research lowered shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Constellation Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Constellation Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $43.46.
CNST stock traded up $0.58 during trading on Wednesday, hitting $36.09. 3,918,785 shares of the company traded hands, compared to its average volume of 205,375. Constellation Pharmaceuticals has a 1 year low of $4.01 and a 1 year high of $59.49. The company has a market cap of $1.21 billion, a PE ratio of -7.22 and a beta of 6.88. The stock’s 50-day simple moving average is $31.65 and its 200 day simple moving average is $14.59. The company has a debt-to-equity ratio of 0.81, a current ratio of 5.19 and a quick ratio of 5.19.
Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.82) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.01. Research analysts expect that Constellation Pharmaceuticals will post -2.99 earnings per share for the current year.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Featured Story: Liquidity
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.